Alexion Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise more than 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $106.04 to $113.46 in the past one month time frame.

The move came after the company reported solid first-quarter 2018 results. Also, the company’s announcement of the Phase 3 study of its C5 complement inhibitor ALXN1210, verified that patients with paroxysmal nocturnal hemoglobinuria disease can safely switch from Soliris.

The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Alexion currently has a Zacks Rank #2 (Buy), while its Earnings ESP is positive.

Investors interested in the Medical - Biomedical and Genetics industry may consider Bellerophon Therapeutics, Inc. (BLPH Quick QuoteBLPH - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ALXN going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
 
See the pot trades we're targeting>>